Kinetics of early therapeutic response as measured by quantitative PCR predicts survival in a murine xenograft model of human T cell acute lymphoblastic leukemia

G. A. Hosler, R. Bash, R. H. Scheuermann

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The identification of prognostic parameters and surrogate markers for defining patient risk has been beneficial in effectively guiding therapy and increasing the survival of leukemia patients. It has been hypothesized that the therapeutic response, as measured by a change in tumor burden during therapy, might serve as a new surrogate marker of survival. Here we describe the development of a murine SCID xenograft model of human T cell acute lymphoblastic leukemia (T-ALL), and the use of a sensitive, quantitative PCR assay for the measurement of tumor levels to investigate the relationships between tumor burden quantification, therapeutic response and survival. Animals engrafted with the CCRF-CEM (CEM) human T-ALL cell line develop leukemia that closely resembles the human disease. Quantitative PCR detects the expanding tumor mass in the peripheral blood of the animals several weeks before death. In response to induction therapy with chemotherapeutic agents, both the level of minimal residual disease (MRD) in peripheral blood at the end of therapy and the rate of tumor reduction in peripheral blood during therapy strongly correlated with animal survival. Thus, these surrogate markers, which can be measured during the early stages of therapy, may help improve patient survival through dynamic risk stratification.

Original languageEnglish (US)
Pages (from-to)1215-1224
Number of pages10
JournalLeukemia
Volume14
Issue number7
StatePublished - 2000

Fingerprint

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Heterografts
Polymerase Chain Reaction
Survival
Biomarkers
Tumor Burden
Therapeutics
Leukemia
Neoplasms
Residual Neoplasm
Secondary Prevention
Cell Line

Keywords

  • Chromosomal rearrangement
  • Flow cytometry
  • Minimal residual disease
  • Quantitative PCR
  • Tal-1
  • Translocation

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Kinetics of early therapeutic response as measured by quantitative PCR predicts survival in a murine xenograft model of human T cell acute lymphoblastic leukemia. / Hosler, G. A.; Bash, R.; Scheuermann, R. H.

In: Leukemia, Vol. 14, No. 7, 2000, p. 1215-1224.

Research output: Contribution to journalArticle

@article{126cdb730bd1464d8101feeba243a200,
title = "Kinetics of early therapeutic response as measured by quantitative PCR predicts survival in a murine xenograft model of human T cell acute lymphoblastic leukemia",
abstract = "The identification of prognostic parameters and surrogate markers for defining patient risk has been beneficial in effectively guiding therapy and increasing the survival of leukemia patients. It has been hypothesized that the therapeutic response, as measured by a change in tumor burden during therapy, might serve as a new surrogate marker of survival. Here we describe the development of a murine SCID xenograft model of human T cell acute lymphoblastic leukemia (T-ALL), and the use of a sensitive, quantitative PCR assay for the measurement of tumor levels to investigate the relationships between tumor burden quantification, therapeutic response and survival. Animals engrafted with the CCRF-CEM (CEM) human T-ALL cell line develop leukemia that closely resembles the human disease. Quantitative PCR detects the expanding tumor mass in the peripheral blood of the animals several weeks before death. In response to induction therapy with chemotherapeutic agents, both the level of minimal residual disease (MRD) in peripheral blood at the end of therapy and the rate of tumor reduction in peripheral blood during therapy strongly correlated with animal survival. Thus, these surrogate markers, which can be measured during the early stages of therapy, may help improve patient survival through dynamic risk stratification.",
keywords = "Chromosomal rearrangement, Flow cytometry, Minimal residual disease, Quantitative PCR, Tal-1, Translocation",
author = "Hosler, {G. A.} and R. Bash and Scheuermann, {R. H.}",
year = "2000",
language = "English (US)",
volume = "14",
pages = "1215--1224",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Kinetics of early therapeutic response as measured by quantitative PCR predicts survival in a murine xenograft model of human T cell acute lymphoblastic leukemia

AU - Hosler, G. A.

AU - Bash, R.

AU - Scheuermann, R. H.

PY - 2000

Y1 - 2000

N2 - The identification of prognostic parameters and surrogate markers for defining patient risk has been beneficial in effectively guiding therapy and increasing the survival of leukemia patients. It has been hypothesized that the therapeutic response, as measured by a change in tumor burden during therapy, might serve as a new surrogate marker of survival. Here we describe the development of a murine SCID xenograft model of human T cell acute lymphoblastic leukemia (T-ALL), and the use of a sensitive, quantitative PCR assay for the measurement of tumor levels to investigate the relationships between tumor burden quantification, therapeutic response and survival. Animals engrafted with the CCRF-CEM (CEM) human T-ALL cell line develop leukemia that closely resembles the human disease. Quantitative PCR detects the expanding tumor mass in the peripheral blood of the animals several weeks before death. In response to induction therapy with chemotherapeutic agents, both the level of minimal residual disease (MRD) in peripheral blood at the end of therapy and the rate of tumor reduction in peripheral blood during therapy strongly correlated with animal survival. Thus, these surrogate markers, which can be measured during the early stages of therapy, may help improve patient survival through dynamic risk stratification.

AB - The identification of prognostic parameters and surrogate markers for defining patient risk has been beneficial in effectively guiding therapy and increasing the survival of leukemia patients. It has been hypothesized that the therapeutic response, as measured by a change in tumor burden during therapy, might serve as a new surrogate marker of survival. Here we describe the development of a murine SCID xenograft model of human T cell acute lymphoblastic leukemia (T-ALL), and the use of a sensitive, quantitative PCR assay for the measurement of tumor levels to investigate the relationships between tumor burden quantification, therapeutic response and survival. Animals engrafted with the CCRF-CEM (CEM) human T-ALL cell line develop leukemia that closely resembles the human disease. Quantitative PCR detects the expanding tumor mass in the peripheral blood of the animals several weeks before death. In response to induction therapy with chemotherapeutic agents, both the level of minimal residual disease (MRD) in peripheral blood at the end of therapy and the rate of tumor reduction in peripheral blood during therapy strongly correlated with animal survival. Thus, these surrogate markers, which can be measured during the early stages of therapy, may help improve patient survival through dynamic risk stratification.

KW - Chromosomal rearrangement

KW - Flow cytometry

KW - Minimal residual disease

KW - Quantitative PCR

KW - Tal-1

KW - Translocation

UR - http://www.scopus.com/inward/record.url?scp=0033947109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033947109&partnerID=8YFLogxK

M3 - Article

C2 - 10914545

AN - SCOPUS:0033947109

VL - 14

SP - 1215

EP - 1224

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 7

ER -